Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Zymeworks Files For Mixed Shelf; Size Not Disclosed

-SEC Filing

byBenzinga Newsdesk

October 1, 2021

1 minute read

-SEC Filing

Morgan Stanley Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $130

By Benzinga Newsdesk

Today, 4:35 AM

Morgan Stanley analyst Jeffrey Hung upgrades Neurocrine Biosciences (NASDAQ:NBIX) from Equal-Weight to Overweight and raises the price target from $120 to $130.

NBIX

FDA
News

Protara Therapeutics-Sponsored Study Titled ‘Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition (THRIVE-1)’ Posted To ClinicalTrials.Gov Website; Study Not Yet Recruiting

By Benzinga Newsdesk

Today, 4:35 AM

https://clinicaltrials.gov/ct2/show/NCT05011370

TARA

Barclays Maintains Underweight on Kroger, Raises Price Target to $37

By vishwanath@benzinga.com

Today, 4:35 AM

Barclays analyst Karen Short maintains Kroger (NYSE:KR) with a Underweight and raises the price target from $35 to $37.

Berenberg Maintains Buy on Bristol-Myers Squibb, Lowers Price Target to $71

By Benzinga Newsdesk

Today, 4:35 AM

Berenberg maintains Bristol-Myers Squibb (NYSE:BMY) with a Buy and lowers the price target from $75 to $71.

BMY

Zymeworks Files For Mixed Shelf; Size Not Disclosed

Related Posts

Morgan Stanley Upgrades Neurocrine Biosciences to Overweight, Raises Price Target to $130

Protara Therapeutics-Sponsored Study Titled ‘Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition (THRIVE-1)’ Posted To ClinicalTrials.Gov Website; Study Not Yet Recruiting

Barclays Maintains Underweight on Kroger, Raises Price Target to $37

Berenberg Maintains Buy on Bristol-Myers Squibb, Lowers Price Target to $71